http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
High-Density Lipoproteins as Biomarkers and Therapeutic Tools
Volume 2. Improvement and Enhancement of HDL and Clinical Applications
This book is the second of two volumes that offer a comprehensive, up-to-date account of current knowledge regarding high-density lipoprotein (HDL), the changes that occur in HDL under different conditions, the clinical applications of HDL, and means of enhancing HDL functionality. In this volume, the focus is on the improvement of HDL, enhancement of its functionality, and the use of HDL for therapeutic purposes. In the first section, up-to-date information is provided on such topics as the tumor regression-promoting and antidiabetic activities of reconstituted HDL containing V156K apolipoprotein A-I, the enhancement of HDL effects by high doses of vitamin C, the benefits derived from incorporation of growth hormones 1 and 2 into rHDL, and the biological functions of omega-3 linolenic acid in rHDL. The enhancement of HDL functionality by policosanol and the resultant benefits are thoroughly examined in a separate section. Readers will also find the latest information on clinical applications of HDL. Here, specific topics include the enhancement of adenoviral gene delivery and the delivery of rapamycin. In documenting the latest knowledge in this field, this volume will be of interest to both researchers and clinicians.
Chapter 1. Improvement of HDL -- 1-1.Clinical application of HDL: Overview -- 1-2.Regression effect of V156K-apoA-I -- 1-3.Anti-diabetic effect of V156K-apoA-I -- 1-4.Vitamin C and HDL -- 1-5.Growth hormone-1 in HDL -- 1-6.Growth hormone-2 in HDL -- 1-7.Omega-3 and HDL -- Chapter 2. HDL as therapeutic tools -- 2-1.Delivery vehicle for therapeutics : Overview -- 2-2.Gene delivery: adenovirus and V156K-apoA-I -- 2-3.Solubilization of rapamycin and delivery -- 2-4.Solubilization of minoxidil and delivery -- Chapter 3. Enhancement of HDL by policosanol: anti-aging and longevity -- 3-1.Policosanol and HDL functionality -- 3-2.Policosanol and raising HDL in zebrafish -- 3-3.Policosanol and CETP inhibition: human trial 8 weeks -- 3-4.Policosanol and blood pressure lowering: human trial 8 weeks -- 3-5.Policosanol blood pressure lowering human trial for 24 weeks -- 3-6.Policosanol and improvement of aortic stiffness -- 3-7.Policosanol and blood pressure lowering in rat model -- 3-8.Twelve week consumption of policosanol and lowering blood pressure -- 3-9.Publication analysis of policosanol-related studies -- 3-10.Athero-protective effects of policosanol and sugar cane wax acid -- 3-11.Cuban sugarcane wax acids and policosanol improved serum lipid profiles -- Summary and perspectives -- Epilogue.